Coronavirus Update: Weekly tally of COVID cases and deaths continues to fall; Moderna lowers vaccine-sales outlook by as much as $3 billion


The global tally of COVID-19 cases fell 17% in the week through Oct. 30 from the previous week, while the death toll fell 5%, the World Health Organization said in its weekly update on the virus.

The omicron variant BA.5 remained dominant globally, accounting for 74.9% of cases sent to a central database. WHO reiterated that newer sublineages of omicron, including BQ.1 and XBB, still appear no more lethal than earlier ones and do not warrant the designation of “variant of concern.”

But BQ.1 rose in prevalence to 9.0% globally from 5.7% a week ago, while XBB rose to 1.5% from 1.0%.

“WHO will continue to closely monitor the XBB and BQ.1 lineages as part of omicron and requests countries to continue to be vigilant, to monitor and report sequences, as well as to conduct independent and comparativeanalyses of the different omicron sublineages,” the agency wrote.

WHO has cautioned that changes in testing and reduced surveillance of the virus are making some of the numbers unreliable and has urged leaders to renew efforts to monitor and track developments.

In the U.S., known cases of COVID remain at their lowest level since mid-April, although the true tally is likely higher given how many people overall are testing at home, where data are not being collected.

The daily average for new cases stood at 39,090 on Wednesday, according to a New York Times tracker, up 3% versus two weeks ago. The daily average for hospitalizations was up 2% to 27,161, while the daily average for deaths was down 6% to 345. 

But cases are climbing in some states, raising concerns among health experts. In Nevada, cases are up 92% from two weeks ago, followed by Missouri, where they are up 75%, Tennessee, where they are up 69%, Louisiana, where they are up 68%, and New Mexico, where they have climbed 54%.

Physicians are reporting high numbers of respiratory illnesses like RSV and the flu earlier than the typical winter peak. WSJ’s Brianna Abbott explains what the early surge means for the coming winter months. Photo illustration: Kaitlyn Wang

Coronavirus Update: MarketWatch’s daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

Other COVID-19 news you should know about:

• COVID vaccine maker Moderna

posted far weaker-than-expected third-quarter earnings on Thursday and lowered full-year sales guidance by up to $3 billion. The Cambridge, Mass.-based biotech firm said advance purchase agreements, or APAs, for delivery this year are now expected to total $18 billion to $19 billion of product sales, down from guidance of $21 billion that it provided when it reported second-quarter earnings. The FactSet consensus is for full-year sales of $21.3 billion. For fiscal 2023, Moderna has APAs of $4.5 billion to $5.5 billion. The FactSet consensus for 2023 sales is for $9.4 billion.

• Virax Biolabs Group Ltd.

stock jumped after the biotechnology company said its triple-virus antigen rapid test kit, which tests for RSV, influenza and COVID, has been launched in the European Union, Dow Jones Newswires reported. The test kit, which can be used in both at-home and point-of-care settings, has also been launched in other markets that accept the CE mark, Virax Biolabs said.

Testing sewage to track viruses has drawn renewed interest after recent outbreaks of diseases like monkeypox and polio. WSJ visited a wastewater facility to find out how the testing works and what it can tell us about public health. Photo illustration: Ryan Trefes

• Royal Caribbean Group

posted its first quarterly profit since the start of the pandemic, but the cruise-line company said it expected a loss for the current quarter, sending its stock lower on Thursday. Load factors were 96% overall and booking volumes were “significantly higher” than in the same period of prepandemic 2019, as the easing of testing and vaccination protocols provided a boost. For the fourth quarter, the company expects adjusted per-share losses of $1.30 to $1.50, compared with the FactSet loss consensus of 71 cents, and projects revenue of “approximately” $2.6 billion, below the FactSet consensus of $2.7 billion. 

• The death of a 3-year-old boy in northwestern China following a suspected gas leak at a locked-down residential compound has triggered a fresh wave of outrage at the country’s stringent zero-COVID policy, CNN reported. The boy’s father said in a social media post on Wednesday that COVID workers tried to prevent him from leaving their compound in Lanzhou, the capital of Gansu province, to seek treatment for his child, resulting in what he believes was a fatal delay. The post was met with an outpouring of public anger and grief, with several related hashtags racking up hundreds of millions of views over the following day on Weibo, China’s Twitter-like platform.

Here’s what the numbers say:

The global tally of confirmed cases of COVID-19 topped 631.4 million on Thursday, while the death toll rose above 6.59 million, according to data aggregated by Johns Hopkins University.

The U.S. leads the world with 97.6 million cases and 1,071,582 fatalities.

The Centers for Disease Control and Prevention’s tracker shows that 226.9 million people living in the U.S., equal to 68.4% of the total population, are fully vaccinated, meaning they have had their primary shots.

So far, just 22.8 million Americans have had the updated COVID booster that targets the original virus and the omicron variants, equal to 7.3% of the overall population.

: Sen. Pat Toomey accuses ESG ratings firms of ‘stonewalling’ Republican investigation

Previous article

: More than $16 billion projected to be spent on 2022 midterms: report

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News